We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
Cap. Flow
+$275M
Cap. Flow %
2.78%
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$123M
2
NPCE icon
Neuropace
NPCE
+$93.1M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$77.8M
4
JANX icon
Janux Therapeutics
JANX
+$77.2M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M

Top Sells

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$94.6M
2
ABCL icon
AbCellera Biologics
ABCL
+$54.5M
3
ADVM
Adverum Biotechnologies
ADVM
+$54.2M
4
MOH icon
Molina Healthcare
MOH
+$38M
5
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Miscellaneous 4.15%
3 Technology 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMO icon
51
Thermo Fisher Scientific
TMO
$230B
$55.6M 0.56%
110,300
– –
OMIC
52
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$54.9M 0.56%
+66,617
New +$51.6M
MREO
53
Mereo BioPharma
MREO
$40.3M
– –
0
– –
BNR
54
Burning Rock Biotech
BNR
$107M
$54.7M 0.55%
185,620
-4,146
-2% -$1.23M
SEM
55
DELISTED
Select Medical
SEM
$53.7M 0.54%
+2,359,162
New +$49M
CMMB
56
Chemomab Therapeutics
CMMB
$19.9M
$49M 0.5%
644,544
– –
TELA icon
57
TELA Bio
TELA
$31.4M
$48.8M 0.49%
3,027,542
– –
APLT
58
DELISTED
Applied Therapeutics
APLT
$46.9M 0.47%
2,257,387
– –
TERN
59
DELISTED
Terns Pharmaceuticals
TERN
$46.5M 0.47%
3,791,204
– –
VTGN icon
60
VistaGen Therapeutics
VTGN
$11.2M
$45.6M 0.46%
482,262
+195,462
+68% +$14.5M
DBTX
61
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$42.5M 0.43%
4,945,192
– –
NVAX icon
62
Novavax
NVAX
$1.53B
$42.5M 0.43%
200,295
+44,462
+29% +$8.15M
TCDA
63
DELISTED
Tricida, Inc. Common Stock
TCDA
$41.5M 0.42%
9,614,280
– –
ORIC icon
64
Oric Pharmaceuticals
ORIC
$1.37B
$41.4M 0.42%
2,337,574
– –
IMA
65
ImageneBio Inc
IMA
$60.6M
$41.2M 0.42%
244,495
– –
SIBN icon
66
SI-BONE Inc
SIBN
$861M
$41.1M 0.42%
1,305,300
– –
MRSN
67
DELISTED
Mersana Therapeutics
MRSN
$38M 0.38%
112,010
+36,310
+48% +$13.7M
IRON icon
68
Disc Medicine
IRON
$3.07B
$37.7M 0.38%
194,207
– –
LOGC
69
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$37.6M 0.38%
8,466,783
– –
VRNA
70
DELISTED
Verona Pharma
VRNA
$37.2M 0.38%
5,694,841
– –
HARP
71
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$36.2M 0.37%
261,131
+32,561
+14% +$6.21M
NSTG
72
DELISTED
NanoString Technologies, Inc.
NSTG
$36M 0.36%
556,000
-66,900
-11% -$4.25M
LENZ
73
LENZ Therapeutics
LENZ
$161M
$34M 0.34%
+158,044
New +$27.5M
TRIL
74
DELISTED
Trillium Therapeutics Inc.
TRIL
$32.2M 0.33%
3,322,300
+157,100
+5% +$1.48M
GHRS icon
75
GH Research
GHRS
$1.92B
$31M 0.31%
+1,428,666
New +$29.2M
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2021 Portfolio in Review

As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.

  • OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
  • OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
  • OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
  • OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
  • OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
  • OrbiMed opened 24 new positions and closed 24 in Q2 2021.
  • OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.